Stay away from concomitant usage of tucatinib with CYP3A substrates, where by minimal concentration changes may well lead to severe or daily life-threatening toxicities. If unavoidable, minimize CYP3A substrate dose according to product labeling.lapatinib will increase the amount or influence of diazepam by influencing hepatic/intestinal enzyme CYP